Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 989-999

  McCarty, Samantha K ^a   Saji, Motoyasu ^a   Zhang, Xiaoli ^a   Jarjoura, David ^a   Fusco, Alfredo ^b   Vasko, Vasyl V ^c   Ringel, Matthew D ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; P21 ACTIVATED KINASE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 2; P21 ACTIVATED KINASE 3; P21 ACTIVATED KINASE 4; P21 ACTIVATED KINASE 6; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CYTOSKELETON; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION;

EID: 78649867086     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0168     Document Type: Article

References (44)

1. Adam L, Vadlamudi R, Mandal M, Chernoff J & Kumar R 2000 Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. Journal of Biological Chemistry 275 12041-12050. (doi:10.1074/jbc.275.16.12041)
2. Beeser A & Chernoff J 2005 Production and use of a cell permeable inhibitor of group A Paks (TAT-PID) to analyze signal transduction. Methods 37 203-207. (doi:10.1016/j.ymeth.2005.05.017) (Pubitemid 41587430)
3. Beeser A, Jaffer ZM, Hofmann C & Chernoff J 2005 Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. Journal of Biological Chemistry 280 36609-36615. (doi:10.1074/jbc. M502306200)
4. Bokoch GM 2003 Biology of the p21-activated kinases. Annual Review of Biochemistry 72 743-781. (doi:10. 1146/annurev.biochem.72.121801.161742)
5. Bright MD, Garner AP & Ridley AJ 2009 PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cellular Signalling 21 1738-1747. (doi:10. 1016/j.cellsig.2009.07.005)
6. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Konicek S, Hom J, Marshall M& Graff JR 2004 Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clinical Cancer Research 10 3448-3456. (doi:10.1158/1078-0432.CCR- 03-0210)
7. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM & Paulin C 1994 Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73 2206-2212. (doi:10.1002/ 1097-0142(19940415)73:8〈2206::AID-CNCR2820730 828〉3.0.CO;2-M)
8. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R & Cobb MH 2000 Stimulation of NFκB activity by multiple signaling pathways requires PAK1. Journal of Biological Chemistry 275 19693-19699. (doi:10.1074/ jbc.M909860199)
9. Goretzki PE, Frilling A, Simon D & Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results in Cancer Research 118 48-63.
10. Gustavsson B, Hermansson A, Andersson AC, Grimelius L, Bergh J, Westermark B & Heldin NE 1996 Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. Molecular and Cellular Endocrinology 121 143-151. (doi:10.1016/0303-7207(96)03859-2)
11. Higuchi M, Onishi K, Kikuchi C & Gotoh Y 2008 Scaffolding function of PAK in the PDK1 - Akt pathway. Nature Cell Biology 10 1356-1364. (doi:10.1038/ ncb1795)
12. Holm S 1979 A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6 65-70.
13. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R & Landberg G 2006 Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Journal of the National Cancer Institute 98 671-680. (doi:10.1093/jnci/djj185)
14. Ishida H, Li K, Yi M & Lemon SM 2007 p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. Journal of Biological Chemistry 282 11836-11848. (doi:10.1074/jbc.M610106200) (Pubitemid 47100711)
15. Jaffer ZM & Chernoff J 2002 p21-activated kinases: three more join the Pak. International Journal of Biochemistry and Cell Biology 34 713-717. (doi:10.1016/S1357-2725(01)00158-3)
16. Kalluri R & Weinberg RA 2009 The basics of epithelial - mesenchymal transition. Journal of Clinical Investigation 119 1420-1428. (doi:10.1172/JCI39104)
17. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA & Bokoch GM 2000 p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). Journal of Biological Chemistry 275 41201-41209. (doi:10.1074/jbc.M006553200)
18. Kumar R & Vadlamudi RK 2002 Emerging functions of p21-activated kinases in human cancer cells. Journal of Cellular Physiology 193 133-144. (doi:10.1002/jcp. 10167)
19. Kumar R, Gururaj AE & Barnes CJ 2006 p21-activated kinases in cancer. Nature Reviews. Cancer 6 459-471. (doi:10.1038/nrc1892)
20. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M & Sonoo H 2000 All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. Journal of Clinical Endocrinology and Metabolism 85 2889-2896. (doi:10. 1210/jc.85.8.2889)
21. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart J-M, Travagli J-P & Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. Journal of Clinical Endocrinology and Metabolism 90 5723-5729. (doi:10.1210/ jc.2005-0285)
22. McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels EG, Burgin SJ, Chen S, Bessler WK, Hofmann C, Ingram DA et al. 2008 Pak1 regulates multiple c-kit mediated Ras - MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 112 4646-4654. (doi:10.1182/blood-2008-04-155085)
23. Molli PR, Li DQ, Murray BW, Rayala SK & Kumar R 2009 PAK signaling in oncogenesis. Oncogene 28 2545-2555. (doi:10.1038/onc.2009.119)
24. 1 to S transition. Cell Cycle 3 71-74.
25. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F & Schlumberger M 2007 Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 17 639-646. (doi:10.1089/thy.2007.0029)
26. Rayala SK, Molli PR & Kumar R 2006 Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Research 66 5985-5988. (doi:10.1158/0008-5472.CAN-06-0978)
27. Rennefahrt UEE, Deacon SW, Parker SA, Devarajan K, Beeser A, Chernoff J, Knapp S, Turk BE & Peterson JR 2007 Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. Journal of Biological Chemistry 282 15667-15678. (doi:10.1074/ jbc.M700253200)
28. Ringel MD 2009 Molecular markers of aggressiveness of thyroid cancer. Current Opinion in Endocrinology, Diabetes, and Obesity 16 361-366. (doi:10.1097/MED. 0b013e32832ff2cb)
29. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD & Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Research 61 6105-6111. (Pubitemid 32762546)
30. Schlumberger M & Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19 1393-1400. (doi:10.1089/thy.2009.1603)
31. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 83 4331-4341. (doi:10. 1210/jc.2008-1102)
32. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, Chan DC, Chan KY et al. 2010 Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. International Journal of Cancer 127 21-31. (doi:10.1002/ijc.25005)
33. Somanath PR, Vijai J, Kichina JV, Byzova T & Kandel ES 2009 The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene 28 2365-2369. (doi:10.1038/onc.2009.114)
34. Tanaka J, Ogura T, Sato H & Hatano M 1987 Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 161 62-72. (doi:10.1016/0042-6822(87)90171-1)
35. Thiery JP 2002 Epithelial - mesenchymal transitions in tumour progression. Nature Reviews. Cancer 2 442-454. (doi:10.1038/nrc822)
36. Thullberg M, Gad A, Beeser A, Chernoff J & Stromblad S 2007 The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity. Oncogene 26 1820-1828. (doi:10.1038/sj.onc.1209983)
37. Tsuji T, Ibaragi S & Hu G-F 2009 Epithelial - mesenchymal transition and cell cooperativity in metastasis. Cancer Research 69 7135-7139. (doi:10.1158/0008-5472.CAN-09-1618)
38. Vadlamudi RK & Kumar R 2003 P21-activated kinases in human cancer. Cancer Metastasis Reviews 22 385-393. (doi:10.1023/A:1023729130497)
39. Vasko VV & Saji M 2007 Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Current Opinion in Oncology 19 11-17. (doi:10.1097/ CCO.0b013e328011ab86)
40. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A et al. 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. PNAS 104 2803-2808. (doi:10.1073/pnas.0610733104)
41. Wang RA, Zhang H, Balasenthil S, Medina D & Kumar R 2006 PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25 2931-2936. (doi:10.1038/sj.onc.1209309)
42. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567.
43. Zhao ZS & Manser E 2005 PAK and other Rho-associated kinases - effectors with surprisingly diverse mechanisms of regulation. Biochemical Journal 386 201-214. (doi:10. 1042/BJ20041638) (Pubitemid 40343777)
44. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE et al. 2006 Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature Neuroscience 9 234-242. (doi:10.1038/nn1630)